|
PTPN21 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.45250000308062E-08 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
1.089240E-01 |
| Stage1-vs-Stage3 |
1.373430E-01 |
| Stage1-vs-Stage4 |
9.98070000000073E-05 |
| Stage2-vs-Stage3 |
1.853850E-02 |
| Stage2-vs-Stage4 |
7.93440000000922E-05 |
| Stage3-vs-Stage4 |
4.457900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
7.66809948871128E-10 |
| Normal-vs-Asian |
1.63558055987778E-12 |
| Caucasian-vs-AfricanAmerican |
4.831000E-01 |
| Caucasian-vs-Asian |
5.720200E-01 |
| AfricanAmerican-vs-Asian |
6.608800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
7.439600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
4.44089209850063E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62503344114384E-12 |
| Normal-vs-Age(81-100Yrs) |
1.76580999999842E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.832000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.860750E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.666200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.966440E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.508200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.635400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.07940000049211E-07 |
| Classical-VS-Follicular |
2.779200E-01 |
| Classical-VS-Other |
5.449000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
5.60769999990995E-07 |
| Tall-VS-Other |
7.917600E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
3.931000E-01 |
| Follicular-VS-Normal |
6.40649755467848E-11 |
| Other-VS-Normal |
1.587980E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
8.43769498715119E-15 |
| N0-vs-N1 |
6.496200E-02 |
|
|
